FDA Approves Hibsago for Chronic Hepatitis B Treatment
The US Food and Drug Administration has approved Hibsago (bepirovirsen) injection to be used alongside existing antiviral therapy for treating specific adults with chronic hepatitis B virus infection who do not have cirrhosis. Hibsago functions as an antisense oligonucleotide designed to target genetic instructions used by the virus to replicate and produce viral proteins.
The approval applies to adults who have maintained suppressed blood levels of HBV while on antiviral therapy for at least six months and have specific surface antigen levels determined by an authorized test. Patients receive the injection subcutaneously for up to 24 weeks alongside their existing medication, with some potentially able to cease all treatment if they meet particular health criteria after completion.
The labeling includes a boxed warning for serious liver reactions and low platelet counts that may cause life-threatening bleeding, alongside warnings for worsened kidney function, severe inflammatory reactions, and administration risks. Healthcare providers should review the full prescribing information for safety details, monitoring requirements, and patient selection guidance.
Key points
- Hibsago is the first FDA-approved antisense oligonucleotide for chronic hepatitis B.
- Indicated for certain adults without cirrhosis who have been on antiviral therapy for at least six months with specific surface antigen levels.
- Carries a boxed warning for serious liver reactions and low platelet counts.
- Common side effects include injection site reactions, fever, fatigue, and headache.
What it means for you
This FDA approval introduces a novel treatment approach that may allow certain chronic hepatitis B patients to eventually discontinue antiviral therapy under specific conditions. Clinicians and pharmacists in Pakistan should note this international regulatory update and consult the Drug Regulatory Authority of Pakistan (DRAP) for any local availability and guidance.
FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment
Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.